{"id":138895,"date":"2025-09-01T20:47:06","date_gmt":"2025-09-02T00:47:06","guid":{"rendered":"https:\/\/cardiologynownews.org\/?p=138895"},"modified":"2026-01-28T15:08:24","modified_gmt":"2026-01-28T20:08:24","slug":"essence-timi-73b-olezarsen-safely-and-effectively-reduces-triglycerides-in-patients-with-moderate-hypertriglyceridemia-and-high-cv-risk","status":"publish","type":"post","link":"https:\/\/cardiologynownews.org\/?p=138895","title":{"rendered":"Essence-TIMI 73b: Olezarsen Safely and Effectively Reduces Triglycerides in Patients With Moderate Hypertriglyceridemia and High CV Risk"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Key Points:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Olezarsen, an anti-sense oligonucleotide targeting APOC3 mRNA, is approved to lower triglycerides (TG) in adults with rare familial chylomicronemia, but its safety and efficacy in a broader populations is unknown.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">In Essence-TIMI 73b, olezarsen significantly reduced TG by ~60% compared with placebo in patients with moderate or severe hypertriglyceridemia and elevated CV risk.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">There was also improvement in other atherogenic lipid measurements with no major safety concerns apart from mild to moderate injection site reactions.\u00a0<\/span><\/li>\n<\/ul>\n<p><!--more--><\/p>\n<p><span style=\"font-weight: 400;\">Olezarsen is a subcutaneously administered ligand-conjugated antisense oligonucleotide that inhibits hepatic production of ApoC-III, which delays TG-rich lipoprotein clearance.\u00a0 By suppressing ApoC-III, olezarsen enhances TG clearance and lowers serum TG levels. While it is approved for rare hypertriglyceridemia syndromes, its safety and efficacy in broader patient populations are uncertain.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">On August 30<\/span><span style=\"font-weight: 400;\">th<\/span><span style=\"font-weight: 400;\"> 2025, the results of \u201cEssence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk\u201d were presented at the European Society of Cardiology Congress in Madrid, Spain.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The trial randomized 1478 patients with TG levels between 150-500 mg\/dL at high cardiovascular risk (defined as established atherosclerotic cardiovascular disease or age \u2265 55 years with diabetes) or those with severe hypertriglyceridemia (\u2265 500mg\/dL) to receive olezarsen 50mg monthly, olezarsen 80mg monthly, or placebo. The primary endpoint was percent change in TG at 6 months. Secondary endpoints included changes in other lipid components.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Overall, 254 participants received the 50mg dose, 766 received the 80mg dose and 329 received placebo. At 6 months, olezarsen significantly reduced TG levels: placebo-adjusted percent changes were -58.4% (95% CI -65.1, -51.7; p &lt;0.001) for the 50mg dose and -60.6% (95% CI -67.1, -54.0; p&lt;0.001) for the 80mg dose. More than 85% of participants treated with olezarsen\u00a0 achieved a TG &lt;150mg\/dL at 6 months, compared to 12.5% of placebo.\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Olezarsen also significantly reduced ApoC-III, non-HDL-C, VLDL-C remnant cholesterol, and ApoB,\u00a0 while increasing in HDL-C at 6 months. There was no difference in in serious adverse events or drug discontinuation between the groups, although non-severe injection site reactions were more common with olezarsen than placebo.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Dr. Brian Bergmark, MD, of Brigham and Women\u2019s Hospital in Boston, MA, concluded: \u201cIn patients with moderate hypertriglyceridemia and heightened CV risk, olezarsen reduced TG level by approximately 60%, [a greater effect] than is possible with current standard of care therapies, with no major safety concerns. These findings support the efficacy and safety of olezarsen for TG lowering in a broad population of patients.\u201d\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Points: Olezarsen, an anti-sense oligonucleotide targeting APOC3 mRNA, is approved to lower triglycerides (TG) in adults with rare familial chylomicronemia, but its safety and efficacy in a broader populations is unknown.\u00a0 In Essence-TIMI 73b, olezarsen significantly reduced TG by ~60% compared with placebo in patients with moderate or severe hypertriglyceridemia and elevated CV risk.\u00a0 [&hellip;]<\/p>\n","protected":false},"author":40618,"featured_media":138253,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[900,8],"tags":[45,901,47,185],"ppma_author":[1072],"class_list":{"0":"post-138895","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-esc-2025","8":"category-news","9":"tag-conference","10":"tag-esc2025","11":"tag-featured","12":"tag-news","13":"author-lucas-marinacci-md"},"authors":[{"term_id":1072,"user_id":40618,"is_guest":0,"slug":"lucas-marinacci-md","display_name":"Lucas Marinacci MD","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/cd81d2064c6f6263719c24aeb738faf718e9bd869c5a840718bc535238ae72f6?s=96&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/138895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/users\/40618"}],"replies":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=138895"}],"version-history":[{"count":1,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/138895\/revisions"}],"predecessor-version":[{"id":138896,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/posts\/138895\/revisions\/138896"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=\/wp\/v2\/media\/138253"}],"wp:attachment":[{"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=138895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=138895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=138895"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/cardiologynownews.org\/index.php?rest_route=%2Fwp%2Fv2%2Fppma_author&post=138895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}